EUVIMEDEUVIMED entdecken
Crossref

Hypoxia-Targeted Responsive Delivery of Doxorubicin and Digoxin for Synergistic Treatment of Triple-Negative Breast Cancer

Lingyan Weng, Min Zhao, Zhongping Chen iD, Li Zhu iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.4c01325 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Lingyan Weng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Special Environmental Medicine, Medical School, Nantong University, Nantong 226019, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Doxorubicin, Digoxin. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To enhance the therapeutic efficacy and safety of triple-negative breast cancer (TNBC) treatment, we developed a hypoxia-responsive drug delivery system utilizing digoxin (DIG) to inhibit HIF-1α and sensitize TNBC to doxorubicin (DOX). DIG, a cardiac steroid with a well-characterized pharmacological mechanism, was encapsulated in micelles composed of methoxy-polyethylene glycol (mPEG) and poly(lactic acid) (PLA) copolymers, incorporating an azobenzene (AZO) trigger for hypoxia-sensitive drug release. The loading ratio of DOX to DIG was optimized based on DIG's minimum effective dose. In vitro and in vivo studies demonstrated that the micelles efficiently delivered their payload to hypoxic tumor regions, enabling rapid drug release. DIG-mediated HIF-1α inhibition enhanced TNBC sensitivity to DOX, leading to significant suppression of both primary tumor growth and pulmonary metastasis. This study presents a promising and clinically feasible strategy for TNBC and other hypoxia-driven malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsDoxorubicinDigoxinAnimalsFemaleHumansMicellesPolyethylene GlycolsMiceCell Line, TumorHypoxia-Inducible Factor 1, alpha SubunitDrug Delivery SystemsXenograft Model Antitumor AssaysPolyestersDrug SynergismDrug LiberationMice, Nude

Stichwörter der Autor:innen

HIF-1αdigoxinhypoxiaresponsive drug deliverysynergistic chemotherapytriple-negative breast cancer

Substanzen

DoxorubicinDigoxinMicellesPolyethylene GlycolsHypoxia-Inducible Factor 1, alpha SubunitPolyestersmethoxy poly(ethylene glycol)-poly(lactide)

Autor:innen und Institutionen

  • Institute of Special Environmental Medicine, Medical School, Nantong University, Nantong 226019, China.

ORCID-Profile: Zhongping Chen, Li Zhu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Weng, L., Zhao, M., Chen, Z., & Zhu, L. (2025). Hypoxia-Targeted Responsive Delivery of Doxorubicin and Digoxin for Synergistic Treatment of Triple-Negative Breast Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01325

Vancouver

Weng L, Zhao M, Chen Z, Zhu L. Hypoxia-Targeted Responsive Delivery of Doxorubicin and Digoxin for Synergistic Treatment of Triple-Negative Breast Cancer. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c01325

BibTeX
@article{Weng2025,
  author = {Weng, Lingyan and Zhao, Min and Chen, Zhongping and Zhu, Li},
  title = {Hypoxia-Targeted Responsive Delivery of Doxorubicin and Digoxin for Synergistic Treatment of Triple-Negative Breast Cancer},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.4c01325}
}
Kostenlos starten →